Compare Visa Inc (V) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Visa Inc vs GeneDx Holdings Corp — how do they compare? Visa Inc trades at $385.45 (market cap $704.20B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Visa Inc is far larger — about 348.6× GeneDx Holdings Corp's market cap, and Visa Inc pays a 0.71% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Visa Inc for 115 Days and GeneDx Holdings Corp for 19 Days on average.
| V | WGS | |
|---|---|---|
Market Cap | $704.20B | $2.02B |
Volume | 6,405,857 | 734,640 |
Sector | Financials | Health |
52-Week High | $384.14 | $167.51 |
52-Week Low | $295.52 | $34.51 |
Typical Hold Time | 115 Days | 19 Days |
Enterprise Value | $714.78B | $2.05B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $385.45, up 3.59% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals, including a 50.78% net income margin and consistent earnings beats. Recent news highlights Visa's AI-driven initiatives like Intelligent Commerce Connect and partnerships to advance stablecoin adoption, positioning it for future growth in digital payments.
Outlook remains positive with a consensus price target of $422.24, implying 9.5% upside. Risks include competitive fintech threats and regulatory pressures. The company's high profitability and strategic focus on AI and digital payments support long-term investment appeal, though valuation multiples are elevated.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
